An observational study in Breast Cancer, sponsored by Pierre Fabre Medicament. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Breast Neoplasms by Pierre Fabre — 1 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Pierre Fabre.
Among the 12 studies in Breast Neoplasms by Pierre Fabre, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 10th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →1 of the 12 studies in Breast Neoplasms by Pierre Fabre is open now, in 1 country.
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 594 across the 5 interventional studies, 155 across the 7 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pierre Fabre Medicament, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Medicament is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Breast Neoplasms by Pierre Fabre, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China
Patients assigned extended adjuvant treatment with neratinib for 12 months for their HER2-positive, early-stage breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Neratinib
Neratinib standard dose 240 mg once daily for 1 year
Duration of Treatment
Median duration of extended adjuvant treatment with neratinib
Time frame: 12 months of treatment
Treatment holds and permanent discontinuations time
Median treatment holds and permanent discontinuations time
Time frame: 12 months of treatment
Patient demographics
% of patients with different demographic characteristics
Time frame: Baseline
Patient characteristics
% of patients with different disease characteristics
Time frame: Baseline
Time to treatment
Median time to treatment since completion of adjuvant regimen
Time frame: Baseline
Prior adjuvant treatments
% of patients with different prior adjuvant treatments
Time frame: Baseline
Dose adjustments
% of patients with dose adjustments
Time frame: 12 months of treatment
Dose intensity
Absolute and relative dose intensity
Time frame: 12 months of treatment
Concomitant medication
% of patients with different concomitant medications
Time frame: 12 months of treatment
Incidence of AESI
Incidence of all grades of adverse events of special interest (AESI)
Time frame: 12 months of treatment
Type of AESI
% of different type of all grades of adverse events of special interest (AESI)
Time frame: 12 months of treatment
Severity of AESI
% of patients with adverse events by severity
Time frame: 12 months of treatment
action taken for AESI
% of patients with action taken against adverse events
Time frame: 12 months of treatment
Time of recurrence
Time from end of neratinib treatment to first invasive recurrence
Time frame: 12 months of treatment; 12 months of follow-up
Recurrent site
% of different site of invasive tumor recurrence
Time frame: 12 months of treatment; 12 months of follow-up
Recurrent size
% of different size of invasive tumor recurrence
Time frame: 12 months of treatment; 12 months of follow-up
QoL - EQ-5D-5L
Median score of the EQ-5D-5L during neratinib treatment. EQ-5D-5L scale as self-reported health-related quality of life.
Time frame: 12 months of treatment
QoL - FACIT D
Median score of the FACIT D during neratinib treatment. FACIT D scale as self-reported health-related quality of life.
Time frame: 12 months of treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2022; primary completion for Dec 2025, 39 months later.
Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 39 months is close to that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.